Foghorn Therapeutics Inc. FHTX NASDAQ

Foghorn Therapeutics Inc. (FHTX) reported total assets of $198.1M and total liabilities of $306.6M for fiscal year 2025, resulting in total equity of $-108.5M.

The company held $158.89M in cash and short-term investments. Total debt stood at $41.27M, with net debt of $-39.61M. The Debt-to-Equity (D/E) ratio was -0.38 (conservative).

Current ratio is 2.73, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of -0.38, current ratio of 2.73 — balance sheet is strong
• MOAT (35/100) — Total assets $198.1M and equity $-108.5M support the company's competitive scale
• VALUE (91/100) — Debt-to-Equity -0.38 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 60/100 with 4/7 criteria passed.

KYMR

Kymera Therapeutics, Inc.

$89.00

-0.96%

EWTX

Edgewise Therapeutics, Inc.

$33.70

+1.63%

STOK

Stoke Therapeutics, Inc.

$35.54

-0.89%

MLYS

Mineralys Therapeutics, Inc.

$30.42

+11.35%

NRIX

Nurix Therapeutics, Inc.

$16.97

+4.11%

GLUE

Monte Rosa Therapeutics, Inc.

$18.23

+4.17%

CGEM

Cullinan Oncology, Inc.

$14.95

+4.18%

RZLT

Rezolute, Inc.

$3.59

+1.13%